Ultrasound S-detect system can improve diagnostic performance of less experienced radiologists in differentiating breast masses: a retrospective dual-centre study

OBJECTIVE

To compare the performance of radiologists when assisted by an S-detect system with that of radiologists or an S-detect system alone in diagnosing breast masses on US images in a dual-centre setting.

METHODS

US images were retrospectively identified 296 breast masses (150 benign, 146 malignant) by investigators at 2 medical centres. Six radiologists from the 2 centres independently analysed the US images and classified each mass into categories 2-5. The radiologists then re-reviewed the images with the use of the S-detect system. The diagnostic value of radiologists alone, S-detect alone, and radiologists + S-detect were analysed and compared.

RESULTS

Radiologists had significantly decreased the average false negative rate (FNR) for diagnosing breast masses using S-detect system (-10.7%) (P < .001) and increased the area under the receiver operating characteristic curve (AUC) from 0.743 to 0.788 (P < .001). Seventy-seven out of 888 US images from 6 radiologists in this study were changed positively (from false positive to true negative or from false negative to true positive) with the S-detect, whereas 39 out of 888 US images were altered negatively.

CONCLUSION

Radiologists had better performance for the diagnosis of malignant breast masses on US images with an S-detect system than without.

ADVANCES IN KNOWLEDGE

The study reported an improvement in sensitivity and AUC particularly for low to intermediate-level radiologists, involved cases and radiologists from 2 different centres, and compared the diagnostic value of using S-detect system for masses of different sizes.

[Digital 3D tomosynthesis in the diagnosis and screening of breast cancer]

Az emlőrák mortalitása és morbiditása a mammográfiás szűrőprogram bevezetésével szignifikánsan csökkent. A teljes gyógyulás szempontjából rendkívül nagy jelentősége van a korai felismerésnek. A 2011-ben az FDA által is elfogadott digitális 3D tomoszintézis a digitális mammográfiát (full-field digital mammography – FFDM) kiegészítő modalitás, mely jól alkalmazható az emlőbetegségek diagnosztikájában és az emlőrák szűrésében. A digitális 3D tomoszintézis alapelve: a vizsgálat során egy adott köríven mozgó röntgencső az emlőről – kis sugárdózissal – rövid idő alatt 10–15 átfedő digitális képet készít. Az így nyert adathalmazból számítógépes feldolgozással vékony szeletvastagságú rétegképek (3D tomoszintézis), valamint rekonstruált, a hagyományos mammográfiás képhez hasonló, ún. szintetikus 2D képek is készülnek. Az előnyök mellett (nagyobb rákfelismerési arány, a kóros képletek, szerkezeti disztorzió, aszimmetrikus denzitás pontosabb megítélése, a felesleges mintavételek számának csökkenése, a szűrésben kisebb visszahívási arány) a hátrányokkal kapcsolatos dilemmák (például sugárterhelés, nagyobb tárhelyigény) ismerete is fontos. Orv Hetil. 2024; 165(37): 1443–1451.

Influence of Acquisition Parameters on Silver Sulfide Nanoparticle Contrast in Photon-Counting Digital Mammography: A Phantom Study

Photon-counting mammography is an emerging modality that allows for spectral imaging and provides a differentiation of material compositions. The development of photon-counting mammography-specific contrast agents has yet to be explored. In this study, the contrast, sensitivity, and organ dose between silver sulfide nanoparticles (Ag2S-NPs) and a clinically approved iodinated agent (iopamidol) were investigated using a contrast-embedded gradient ramp phantom and a prototype scanner. For a given agent, the signal intensity increased with concentration, tube voltage (kV), and high bin fraction, while remaining constant with the tube current exposure time product (mAs). Moreover, Ag2S-NPs produced significantly stronger contrast and improved sensitivity compared to iodine, especially when imaged at lower tube energies. Therefore, the use of photon-counting techniques and a silver-based contrast agent may markedly increase the contrast and contrast-to-noise ratios or reduce the radiation dose for contrast-enhanced mammography. Silver may be better suited than iodine for contrast agent development for spectral photon-counting mammography.

Digital Breast Tomosynthesis: an Overview

Breast cancer is emerging as the most common malignancy in Indian women. Mammography is one of the few screening modalities available to the modern world that has proved itself of much use by aiding early detection and treatment of non-palpable, node-negative breast cancers. However, due to its two-dimensional nature, many cases of malignancies are still missed, to be detected at a later date or by an alternate modality. In 2011, FDA approved the supplemental use of digital breast tomosynthesis (DBT) in screening and diagnostic set ups. The acquisition of multiple low-dose projection images of the compressed parenchyma provided a 'third' dimension to the mammogram whereby the breast tissue could be seen layer by layer on the workstation. It improves cancer detection rate, and reduces recall rate and false-positive findings by improving lesion characterization. The current review discusses the principle of DBT with a comprehensive study of the literature.

Supplementary Information

The online version contains supplementary material available at 10.1007/s13193-021-01310-y.

Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis

Background

To investigate the performance of primary ultrasound (P-US) screening for breast cancer, and that of supplemental ultrasound (S-US) screening for breast cancer after negative mammography (MAM).

Methods

Electronic databases (PubMed, Scopus, Web of Science, and Embase) were systematically searched to identify relevant studies published between January 2003 and May 2018. Only high-quality or fair-quality studies reporting any of the following performance values for P-US or S-US screening were included: sensitivity, specificity, cancer detected rate (CDR), recall rate (RR), biopsy rate (BR), proportion of invasive cancers among screening-detected cancers (ProIC), and proportion of node-negative cancers among screening-detected invasive cancers (ProNNIC).

Results

Twenty-three studies were included, including 12 studies in which S-US screening was used after negative MAM and 11 joint screening studies in which both primary MAM (P-MAM) and P-US were used. Meta-analyses revealed that S-US screening could detect 96% [95% confidential intervals (CIs): 82 to 99%] of occult breast cancers missed by MAM and identify 93% (95% CIs: 89 to 96%) of healthy women, with a CDR of 3.0/1000 (95% CIs: 1.8/1000 to 4.6/1000), RR of 8.8% (95% CIs: 5.0 to 13.4%), BR of 3.9% (95% CIs: 2.7 to 5.4%), ProIC of 73.9% (95% CIs: 49.0 to 93.7%), and ProNNIC of 70.9% (95% CIs: 46.0 to 91.6%). Compared with P-MAM screening, P-US screening led to the recall of significantly more women with positive screening results [1.5% (95% CIs:0.6 to 2.3%), P = 0.001] and detected significantly more invasive cancers [16.3% (95% CIs: 10.6 to 22.1%), P < 0.001]. However, there were no significant differences for other performance measures between the two screening methods, including sensitivity, specificity, CDR, BR, and ProNNIC.

Conclusions

Current evidence suggests that S-US screening could detect occult breast cancers missed by MAM. P-US screening has shown to be comparable to P-MAM screening in women with dense breasts in terms of sensitivity, specificity, cancer detection rate, and biopsy rate, but with higher recall rates and higher detection rates for invasive cancers.

Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines

DESCRIPTION

The European Commission Initiative for Breast Cancer Screening and Diagnosis guidelines (European Breast Guidelines) are coordinated by the European Commission's Joint Research Centre. The target audience for the guidelines includes women, health professionals, and policymakers.

METHODS

An international guideline panel of 28 multidisciplinary members, including patients, developed questions and corresponding recommendations that were informed by systematic reviews of the evidence conducted between March 2016 and December 2018. GRADE (Grading of Recommendations Assessment, Development and Evaluation) Evidence to Decision frameworks were used to structure the process and minimize the influence of competing interests by enhancing transparency. Questions and recommendations, expressed as strong or conditional, focused on outcomes that matter to women and provided a rating of the certainty of evidence.

RECOMMENDATIONS

This synopsis of the European Breast Guidelines provides recommendations regarding organized screening programs for women aged 40 to 75 years who are at average risk. The recommendations address digital mammography screening and the addition of hand-held ultrasonography, automated breast ultrasonography, or magnetic resonance imaging compared with mammography alone. The recommendations also discuss the frequency of screening and inform decision making for women at average risk who are recalled for suspicious lesions or who have high breast density.

Do radiological research articles apply the term "pilot study" correctly? Systematic review

AIM

To determine what proportion of radiological studies used the term "pilot" correctly.

MATERIAL AND METHODS

Indexed studies describing themselves as a "pilot" in their title were identified from four indexed radiological journals. The aim was to identify 20 consecutive, eligible studies from each journal, as this sample size was deemed sufficient to be representative as to how this methodological description was employed by authors of radiological articles. Data were extracted relating to study design and data presented. The review was reported according to PRISMA guidelines.

RESULTS

The search string used identified 658 records across the four targeted journals. Ultimately, 78 reviews describing 5,572 patients were selected for systematic review. Median sample size was just 20 patients. No individual study qualified as a genuine pilot study when assessed against the a priori criteria. In reality, the large majority (66 studies, 84.6%) were framed as studies of diagnostic test accuracy. A significant proportion (21 studies, 26.9%) was retrospective, and the overwhelming majority were conducted in single centres (76 centres, 94.7%). Most (55 studies, 70.5%) stated no rationale for their sample size, and no study presented a formal power calculation.

CONCLUSION

Radiological "pilot" studies are mostly underpowered studies of diagnostic test accuracy. In order to have scientific credibility, authors, reviewers, and editors of radiological journals are encouraged to familiarise themselves with different methodological study designs and their precise implications.

Personalized breast cancer screening strategies: A systematic review and quality assessment

BACKGROUND

The effectiveness of breast cancer screening is still under debate. Our objective was to systematically review studies assessing personalized breast cancer screening strategies based on women's individual risk and to conduct a risk of bias assessment.

METHODS

We followed the standard methods of The Cochrane Collaboration and PRISMA declaration and searched the MEDLINE, EMBASE and Clinical Trials databases for studies published in English. The quality of the studies was assessed using the ISPOR-AMCP-NPC Questionnaire and The Cochrane Risk of Bias Tool. Two independent reviewers screened full texts and evaluated the risk of bias.

RESULTS

Out of the 1533 initially retrieved citations, we included 13 studies. Three studies were randomized controlled trials, while nine were mathematical modeling studies, and one was an observational pilot study. The trials are in the recruitment phase and have not yet reported their results. All three trials used breast density and age to define risk groups, and two of them included family history, previous biopsies, and genetic information. Among the mathematical modeling studies, the main risk factors used to define risk groups were breast density, age, family history, and previous biopsies. Six studies used genetic information to define risk groups. The most common outcome measures were the gain in quality-adjusted life years (QALY), absolute costs, and incremental cost-effectiveness ratio (ICER), while the main outcome in the observational study was the detection rate. In all models, personalized screening strategies were shown to be effective. The randomized trials were of good quality. The modeling studies showed moderate risk of bias but there was wide variability across studies. The observational study showed a low risk of bias but its utility was moderate due to its pilot design and its relatively small scale.

CONCLUSIONS

There is some evidence of the effectiveness of screening personalization in terms of QUALYs and ICER from the modeling studies and the observational study. However, evidence is lacking on feasibility and acceptance by the target population.

REVIEW REGISTRATION

PROSPERO: CRD42018110483.

Interpretation of breast cancer screening guideline for Chinese women

Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women. It is imperative to develop breast cancer screening guideline that is suitable for Chinese women. By summarizing the current evidence on breast cancer screening in Chinese women, and referring to the latest guidelines and consensus on breast cancer screening in Europe, the United States, and East Asia, the China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) have formulated population-based guideline for breast cancer screening in Chinese women. The guideline provides recommendations on breast cancer screening for Chinese women at average or high risk of breast cancer according to the following three aspects: age of screening, screening methods, and screening interval. This article provides more detailed information to support the recommendations in this guideline and to provide more direction for current breast cancer screening practices in China.

Mammography Screening 2.0 - How Can Risk-Adapted Screening be Implemented in Clinical Practice?: Results of a Focus Group Discussion with Experts in the RISIKOLOTSE.DE Project

INTRODUCTION

The mammography screening programme has been the subject of criticism for some time. Invitation to take part is currently based only on the risk factors of age and female sex, whereby women with an above-average risk are screened too seldom and women with a low risk are possibly screened too often. In future, an individualised risk assessment could make a risk-adapted procedure possible in breast cancer screening. In the RISIKOLOTSE.DE project, schemes are devised to calculate the individual breast cancer risk and evaluate the results. The aim is to assist doctors and screening participants in participatory decision-making. To gauge the baseline situation in the target groups, qualitative and quantitative surveys were conducted.

METHOD

At the start of the project, a guideline-based focus group discussion was held with 15 doctors and representatives of the public health service. The transcript of this discussion was evaluated by means of a qualitative content analysis.

RESULTS

The participants assessed the concept of risk-adapted screening positively overall. At the same time, the majority of them were of the opinion that the results of individualised risk calculation can be understood and evaluated adequately only by doctors. The great communication requirement and lack of remuneration were given as practical obstacles to implementation.

DISCUSSION

The suggestions and new ideas from the focus group ranged from administrative and regulatory changes to new forms of counselling and adaptable practice aids. An important indicator for the RISIKOLOTSE.DE conception and for planning future surveys was that risk calculation for mammography screening 2.0 was regarded as a purely medical function and that the concept of participatory decision-making played hardly any part in the discussion.

Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts: Interim Report of a Prospective Comparative Trial

PURPOSE

Debate on adjunct screening in women with dense breasts has followed legislation requiring that women be informed about their mammographic density and related adjunct imaging. Ultrasound or tomosynthesis can detect breast cancer (BC) in mammography-negative dense breasts, but these modalities have not been directly compared in prospective trials. We conducted a trial of adjunct screening to compare, within the same participants, incremental BC detection by tomosynthesis and ultrasound in mammography-negative dense breasts.

PATIENTS AND METHODS

Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts is a prospective multicenter study recruiting asymptomatic women with mammography-negative screens and dense breasts. Eligible women had tomosynthesis and physician-performed ultrasound with independent interpretation of adjunct imaging. Outcome measures included cancer detection rate (CDR), number of false-positive (FP) recalls, and incremental CDR for each modality; these were compared using McNemar's test for paired binary data in a preplanned interim analysis.

RESULTS

Among 3,231 mammography-negative screening participants (median age, 51 years; interquartile range, 44 to 78 years) with dense breasts, 24 additional BCs were detected (23 invasive): 13 tomosynthesis-detected BCs (incremental CDR, 4.0 per 1,000 screens; 95% CI, 1.8 to 6.2) versus 23 ultrasound-detected BCs (incremental CDR, 7.1 per 1,000 screens; 95% CI, 4.2 to 10.0), P = .006. Incremental FP recall occurred in 107 participants (3.33%; 95% CI, 2.72% to 3.96%). FP recall (any testing) did not differ between tomosynthesis (FP = 53) and ultrasound (FP = 65), P = .26; FP recall (biopsy) also did not differ between tomosynthesis (FP = 22) and ultrasound (FP = 24), P = .86.

CONCLUSION

The Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts' interim analysis shows that ultrasound has better incremental BC detection than tomosynthesis in mammography-negative dense breasts at a similar FP-recall rate. However, future application of adjunct screening should consider that tomosynthesis detected more than 50% of the additional BCs in these women and could potentially be the primary screening modality.

Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force

BACKGROUND

Screening mammography has lower sensitivity and specificity in women with dense breasts, who experience higher breast cancer risk.

PURPOSE

To perform a systematic review of reproducibility of Breast Imaging Reporting and Data System (BI-RADS) density categorization and test performance and clinical outcomes of supplemental screening with breast ultrasonography, magnetic resonance imaging (MRI), and digital breast tomosynthesis (DBT) in women with dense breasts and negative mammography results.

DATA SOURCES

MEDLINE, PubMed, EMBASE, and Cochrane database from January 2000 to July 2015.

STUDY SELECTION

Studies reporting BI-RADS density reproducibility or supplemental screening results for women with dense breasts.

DATA EXTRACTION

Quality assessment and abstraction of 24 studies from 7 countries; 6 studies were good-quality.

DATA SYNTHESIS

Three good-quality studies reported reproducibility of BI-RADS density; 13% to 19% of women were recategorized between "dense" and "nondense" at subsequent screening. Two good-quality studies reported that sensitivity of ultrasonography for women with negative mammography results ranged from 80% to 83%; specificity, from 86% to 94%; and positive predictive value (PPV), from 3% to 8%. The sensitivity of MRI ranged from 75% to 100%; specificity, from 78% to 94%; and PPV, from 3% to 33% (3 studies). Rates of additional cancer detection with ultrasonography were 4.4 per 1000 examinations (89% to 93% invasive); recall rates were 14%. Use of MRI detected 3.5 to 28.6 additional cancer cases per 1000 examinations (34% to 86% invasive); recall rates were 12% to 24%. Rates of cancer detection with DBT increased by 1.4 to 2.5 per 1000 examinations compared with mammography alone (3 studies). Recall rates ranged from 7% to 11%, compared with 7% to 17% with mammography alone. No studies examined breast cancer outcomes.

LIMITATIONS

Good-quality evidence was sparse. Studies were small and CIs were wide. Definitions of recall were absent or inconsistent.

CONCLUSION

Density ratings may be recategorized on serial screening mammography. Supplemental screening of women with dense breasts finds additional breast cancer but increases false-positive results. Use of DBT may reduce recall rates. Effects of supplemental screening on breast cancer outcomes remain unclear.

PRIMARY FUNDING SOURCE

Agency for Healthcare Research and Quality.

Breast density across a regional screening population: effects of age, ethnicity and deprivation

OBJECTIVE

Breast density (BD) is a recognized risk factor for breast cancer. This study maps density variation across a screening population and identifies demographic distinctions, which may affect density and so impact on cancer development/detection. We focus on the relationship between age, ethnicity and socioeconomic status on density.

METHODS

This retrospective study on a screening population adheres to local patient confidentiality requirements. BD data from screening mammograms (March 2013 to September 2014) were measured using Volpara((®))Density(™) software (Volpara((®))Solutions(™), Wellington, New Zealand). Demographics, including patient age, ethnicity and deprivation index, were obtained from our breast screening database and analysed with respect to breast volume (BV), fibroglandular tissue volume (FGV), Volpara %BD and Volpara Grade (1-4 scale, lowest to highest).

RESULTS

Study population demonstrates little difference for BV with respect to age, but a slight negative trend was noted when FGV was evaluated vs age. Density was linked to ethnicity: females of Chinese ethnicity had higher BD largely reflecting their lower BV. Females in the most deprived quintiles tended to have larger and therefore less dense breasts.

CONCLUSION

Our mapping of BD in a regional screening programme demonstrates impact of age, ethnicity and socioeconomic status on BD with attendant implications for breast cancer risk.

ADVANCES IN KNOWLEDGE

BD is a known risk factor for development of breast cancer. Density trends in a large regional screening population with respect to age, ethnicity and socioeconomics may eventually help identify the risk of breast cancer in certain subsets of the population.

Imaging surveillance programs for women at high breast cancer risk in Europe: Are women from ethnic minority groups adequately included? (Review)

Women from ethnic minority groups, including immigrants and refugees are reported to have low breast cancer (BC) screening rates. Active, culturally-sensitive outreach is vital for increasing participation of these women in BC screening programs. Women at high BC risk and who belong to an ethnic minority group are of special concern. Such women could benefit from ongoing trials aimed at optimizing screening strategies for early BC detection among those at increased BC risk. Considering the marked disparities in BC survival in Europe and its enormous and dynamic ethnic diversity, these issues are extremely timely for Europe. We systematically reviewed the literature concerning European surveillance studies that had imaging in the protocol and that targeted women at high BC risk. The aim of the present review was thereby to assess the likelihood that women at high BC risk from minority ethnic groups were adequately included in these surveillance programs. Twenty-seven research groups in Europe reported on their imaging surveillance programs for women at increased BC risk. The benefit of strategies such as inclusion of magnetic resonance imaging and/or more intensive screening was clearly documented for the participating women at increased BC risk. However, none of the reports indicated that sufficient outreach was performed to ensure that women at increased BC risk from minority ethnic groups were adequately included in these surveillance programs. On the basis of this systematic review, we conclude that the specific screening needs of ethnic minority women at increased BC risk have not yet been met in Europe. Active, culturally-sensitive outreach is needed to identify minority women at increased BC risk and to facilitate their inclusion in on-going surveillance programs. It is anticipated that these efforts would be most effective if coordinated with the development of European-wide, population-based approaches to BC screening.

Changing patterns of microcalcification on screening mammography for prediction of breast cancer

BACKGROUND

The presence of microcalcification on mammography is one of the earliest signs in breast cancer detection. However, it is difficult to distinguish malignant calcifications from benign calcifications. The aim of this study is to evaluate correlation between changing patterns of microcalcification on screening mammography and malignant breast lesions.

METHODS

Medical records and diagnostic images of 67 women who had previously undergone at least two digital mammograms at least 6 months apart and underwent mammography-guided needle localization and surgical excision between 2011 and 2013 were retrospectively reviewed and analyzed.

RESULTS

Breast cancer was detected in the surgical specimens of 20 patients (29.9 %). Annual change of extent of microcalcification on mammography showed statistically significant correlation with pathologic outcome (P = 0.023). The changing pattern of new appearance or increased extent of microcalcification on mammography had positive predictive value of 54.8 % for breast cancer, and it was a statistically significant predictor for breast cancer (P = 0.012). Shape or number change of microcalcification without increased extent had less accurate predictive value for breast cancer, particularly in women younger than 50 years (P < 0.001).

CONCLUSIONS

This study showed that the pattern of increased extent of microcalcification on screening mammography was a significant predictor for breast cancer. We suggest that mammography-guided needle localization and surgical excision should be considered when increased extent of microcalcification is observed on screening mammography and closed follow-up without pathologic confirmation can be permitted if absence of extension of microcalcification was confirmed in women younger than 50 years.

Feasibility study of a breast density measurement within a direct photon-counting mammography scanner system

PURPOSE

To evaluate the clinical feasibility of breast density measurements by a new application within a direct photon-counting mammography scanner system.

MATERIALS AND METHODS

A retrospective study of consecutive women who underwent mammography using a direct photon-counting mammography scanner system (MicroDose mammography SI; Philips Digital Mammography Sweden AB) was performed at the authors' institution between September and December 2013. Quantitative volumetric glandularity measurements were performed automatically for each acquired mammographic image using an application (Breast Density Measurement; Philips Digital Mammography Sweden AB). The quantitative volumetric glandularity of each breast was defined as the average values for the mediolateral oblique (MLO) and craniocaudal (CC) mammogram views.

RESULTS

Of the 44 women who underwent bilateral mammogram acquisitions, the breast density measurements were performed successfully in 40 patients (90.9%). A very good to excellent correlation in the quantitative breast density measurements acquired from the MLO and CC images was obtained in the 40 evaluable patients (R = 0.99).

CONCLUSION

The calculated volumetric glandularity using this new application should correspond well with the true volumetric density of each breast.

Future directions for the early detection of recurrent breast cancer

The main goal of follow-up care after breast cancer treatment is the early detection of disease recurrence. In this review, we emphasize the multidisciplinary approach to this continuity of care from surgery, medical oncology, and radiology. Challenges within each setting are briefly addressed as a means of discussion for the future directions of an effective and efficient surveillance plan of post-treatment breast cancer care.